170 related articles for article (PubMed ID: 19805570)
1. Polyamine transport as a target for treatment of Pneumocystis pneumonia.
Liao CP; Phanstiel O; Lasbury ME; Zhang C; Shao S; Durant PJ; Cheng BH; Lee CH
Antimicrob Agents Chemother; 2009 Dec; 53(12):5259-64. PubMed ID: 19805570
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis mediates overexpression of antizyme inhibitor resulting in increased polyamine levels and apoptosis in alveolar macrophages.
Liao CP; Lasbury ME; Wang SH; Zhang C; Durant PJ; Murakami Y; Matsufuji S; Lee CH
J Biol Chem; 2009 Mar; 284(12):8174-84. PubMed ID: 19158080
[TBL] [Abstract][Full Text] [Related]
3. Effect of a bis-benzyl polyamine analogue on Pneumocystis carinii.
Merali S; Saric M; Chin K; Clarkson AB
Antimicrob Agents Chemother; 2000 Feb; 44(2):337-43. PubMed ID: 10639359
[TBL] [Abstract][Full Text] [Related]
4. Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia.
Lasbury ME; Merali S; Durant PJ; Tschang D; Ray CA; Lee CH
J Biol Chem; 2007 Apr; 282(15):11009-20. PubMed ID: 17314093
[TBL] [Abstract][Full Text] [Related]
5. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis pneumonia.
Lasbury ME; Durant PJ; Ray CA; Tschang D; Schwendener R; Lee CH
J Immunol; 2006 Jun; 176(11):6443-53. PubMed ID: 16709801
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats.
Sun P; Tong Z
Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652
[TBL] [Abstract][Full Text] [Related]
7. Defining the molecular requirements for the selective delivery of polyamine conjugates into cells containing active polyamine transporters.
Wang C; Delcros JG; Cannon L; Konate F; Carias H; Biggerstaff J; Gardner RA; Phanstiel IV O
J Med Chem; 2003 Nov; 46(24):5129-38. PubMed ID: 14613316
[TBL] [Abstract][Full Text] [Related]
8. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery.
Lasbury ME; Durant PJ; Bartlett MS; Smith JW; Lee CH
Clin Diagn Lab Immunol; 2003 Mar; 10(2):293-302. PubMed ID: 12626457
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory cells are sources of polyamines that induce alveolar macrophage to undergo apoptosis during Pneumocystis pneumonia.
Liao CP; Lasbury ME; Wang SH; Zhang C; Durant PJ; Tschang D; Lee CH
J Eukaryot Microbiol; 2006; 53 Suppl 1():S134-5. PubMed ID: 17169031
[No Abstract] [Full Text] [Related]
10. Effect of nicotine on lung S-adenosylmethionine and development of Pneumocystis pneumonia.
Shivji M; Burger S; Moncada CA; Clarkson AB; Merali S
J Biol Chem; 2005 Apr; 280(15):15219-28. PubMed ID: 15668255
[TBL] [Abstract][Full Text] [Related]
11. N1-substituent effects in the selective delivery of polyamine conjugates into cells containing active polyamine transporters.
Gardner RA; Delcros JG; Konate F; Breitbeil F; Martin B; Sigman M; Huang M; Phanstiel O
J Med Chem; 2004 Nov; 47(24):6055-69. PubMed ID: 15537360
[TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid in combination with primaquine clears pneumocystis infection.
Lei GS; Zhang C; Shao S; Jung HW; Durant PJ; Lee CH
PLoS One; 2013; 8(1):e53479. PubMed ID: 23308231
[TBL] [Abstract][Full Text] [Related]
13. Ant 4,4, a polyamine-anthracene conjugate, induces cell death and recovery in human promyelogenous leukemia cells (HL-60).
Traquete R; Ghani RA; Phanstiel O; Wallace HM
Amino Acids; 2013 Apr; 44(4):1193-203. PubMed ID: 23292094
[TBL] [Abstract][Full Text] [Related]
14. Molecular requirements for targeting the polyamine transport system. Synthesis and biological evaluation of polyamine-anthracene conjugates.
Wang C; Delcros JG; Biggerstaff J; Phanstiel O
J Med Chem; 2003 Jun; 46(13):2672-82. PubMed ID: 12801231
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacies of chitosan against Pneumocystis pneumonia of immunosuppressed rat.
Liu AB; Pu Y; Zheng YQ; Cai H; Ye B
Parasite Immunol; 2014 Jul; 36(7):292-302. PubMed ID: 24702055
[TBL] [Abstract][Full Text] [Related]
16. SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs.
Standaert-Vitse A; Aliouat-Denis CM; Martinez A; Khalife S; Pottier M; Gantois N; Dei-Cas E; Aliouat el M
PLoS One; 2015; 10(6):e0130358. PubMed ID: 26103633
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator production in a rat model of Pneumocystis carinii pneumonia.
Angelici E; Contini C; Spezzano M; Romani R; Carfagna P; Serra P; Canipari R
Microbiol Immunol; 2001; 45(8):605-11. PubMed ID: 11592634
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study.
Awad WB; Asaad A; Al-Yasein N; Najjar R
BMC Infect Dis; 2020 Jun; 20(1):400. PubMed ID: 32503449
[TBL] [Abstract][Full Text] [Related]
19. A critical role for CARD9 in pneumocystis pneumonia host defence.
Kottom TJ; Nandakumar V; Hebrink DM; Carmona EM; Limper AH
Cell Microbiol; 2020 Oct; 22(10):e13235. PubMed ID: 32548948
[TBL] [Abstract][Full Text] [Related]
20. Baicalin tetrazole acts as anti-pneumocystis carinii pneumonia candidate in immunosuppressed rat model.
Chen L; Zhang X; Peng X; Yang Y; Yu H
Microb Pathog; 2019 Jul; 132():59-65. PubMed ID: 31002962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
